drugset / Trial / NCT03208426

Sequential Versus Quadruple Therapy in the Second-line Treatment

NCT03208426

Phase 4 Unknown 240 enrolled National Taiwan University Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Objectives: A recent randomized trial showed that 14-day sequential therapy containing high dose proton pump inhibitor was higher than 95% in the first line treatment. However, whether the 14-day sequential therapy is more effective than 10-day bismuth quadruple therapy remains unknown. Therefore, the investigators aimed to compare the eradication rates and long term re-infection rates of sequential therapy for 14 days versus bismuth quadruple therapy for 10 days in the second line treatment.

Timeline

Start
2017-10-01
Primary completion
2019-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1000 mg
Comparator BISMUTH OXIDE Unknown 120 mg
Subject Clarithromycin Small molecule 500 mg
Subject Esomeprazole Small molecule 40 mg
Subject Metronidazole Small molecule 500 mg
Comparator Tetracycline Unknown 500 mg